-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Approval for Nicethamide API
Category:
TIME：2025-01-02
On December 30, Nicethamide, developed by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms. To date, the Group has a total of 67 API products.
According to available information, nicethamide API is primarily used for central respiratory depression and respiratory depression caused by various etiologies; it is a class of central stimulant drugs, and its injectable formulation is mainly indicated for the treatment of conditions such as respiratory or circulatory failure.
In the first batch of “Challenge-based Recruitment” projects for critical core technologies and products in the industrial sector, announced by the Hebei Provincial Department of Industry and Information Technology in January of this year, Guangxiang Pharmaceutical Group successfully secured the contract to develop a manufacturing process for nicethamide API. This project primarily addresses the challenges associated with nicethamide—its susceptibility to oxidation, stringent transportation and storage requirements, and difficulties in scaling up production—thereby laying the foundation for the industrial-scale production of nicethamide API.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
